Research programme: therapeutic antibodies - Zebra Biologics

Drug Profile

Research programme: therapeutic antibodies - Zebra Biologics

Latest Information Update: 12 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zebra Biologics
  • Developer AbbVie; Zebra Biologics
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Diabetes mellitus; Neurological disorders; Obesity
  • Research Inflammation

Most Recent Events

  • 09 Jan 2017 Zebra Biologics and AbbVie agree to co-develop therapeutic antibodies in USA for Inflammation
  • 09 Jan 2017 Early research in Inflammation in USA (Parenteral)
  • 11 Nov 2013 Preclinical trials in Cancer, Diabetes mellitus, Neurological disorders and Obesity in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top